Company profile: Grin Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted therapies for rare, severe neurodevelopmental disorders.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Grin Therapeutics
Addex Therapeutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage, orally available small-molecule allosteric modulators. Pipeline includes ADX71149, an mGlu2 positive allosteric modulator in Phase 2 for epilepsy; dipraglurant, an mGlu5 negative allosteric modulator for post-stroke/TBI sensorimotor recovery; and GABAB PAM programs for substance use disorder (licensed to Indivior) and chronic cough.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Addex Therapeutics company profile →
JuvLabs
HQ: Isle of Man
Website
- Description: Provider of biotech therapies and products to modify aging and address age-related diseases. Through its JuvRx therapeutics division, the company develops novel treatments targeting fibrosis and inflammatory conditions, including serpin-based PAI-1 inhibitors, TGF-β modulation drugs, NAD+ metabolism enhancers (with the Buck Institute), ketone-based therapies for heart failure, and an oral plasmalogen precursor to restore cell function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JuvLabs company profile →
Serina Therapeutics
HQ: United States
Website
- Description: Provider of proprietary polymer-based drug delivery and therapeutics, including the POZ Platform for programmable, targeted, continuous small-molecule delivery (IV/SC/IM); SER-252 for advanced Parkinson’s Disease; CNS small-molecule conjugates; POZ-lipid LNPs for mRNA immunology; and ADCs that increase DAR to improve efficacy, addressing cancer, inflammation, pain and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serina Therapeutics company profile →
Penumbra
HQ: United States
Website
- Description: Provider of neurovascular and peripheral vascular devices, including: Lightning Flash mechanical thrombectomy for pulmonary embolism and venous thrombus; Penumbra System for mechanical thrombectomy in acute ischemic stroke due to intracranial large vessel occlusions; Artemis Neuro Evacuation Device for controlled aspiration; Indigo System for arterial/venous clot removal; PC400 coils for aneurysms and malformations; and POD400/PAC400 for predictable vessel occlusion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Penumbra company profile →
Sage Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sage Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Grin Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Grin Therapeutics
2.2 - Growth funds investing in similar companies to Grin Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Grin Therapeutics
4.2 - Public trading comparable groups for Grin Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →